<DOC>
	<DOCNO>NCT00844012</DOCNO>
	<brief_summary>Because ovarian sex steroid fluctuation menstrual cycle implicate pathogenesis endometriosis-related chronic pelvic pain ( CPP ) , oral contraceptive ( OCs ) use non-contraceptive indication disorder . To date , OCs widely use medical treatment patient endometriosis , addition , recently experiment post-surgical therapy . Traditional cyclic regimen , 21 day active pill 7 day placebo suspension , usually adopt . Furthermore , recent study suggest long-term continuous OCs use effective postoperative period second- third- line treatment cyclic regimen failure . In study combine treatment ethinilestradiol ( 0.02 mg ) plus desogestrel ( 0.15 mg ) use compare baseline ciproterone acetate . A recent study show deep ovarian endometrial suppression continuous OCs comparison cyclic OCs , provide physiological rationale continuous OCs use noncontraceptive indication . Furthermore , date , study compare post-operative continuous versus cyclic OCs patient endometriosis-related CPP .</brief_summary>
	<brief_title>Continuous Postoperative Use Low-Dose Combined Oral Contraceptivesfor Endometriosis-Related Chronic Pelvic Pain</brief_title>
	<detailed_description>Premenopausal woman endometriosis-related CPP schedule laparoscopic surgery Academic Department Gynecology consecutively enrol . Subjects hystologically confirm endometriosis laparoscopy ( stage I-IV American Society Reproductive Medicine ) , subjective severity pelvic pain use visual analogue scale ( VAS 1-100 ) least 70 , without immediate desire pregnancy enrol . Briefly , patient undergo conservative laparoscopic surgery endometriosis . Thereafter , low-dose monophasic OC contain 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol ( Belara® , Grunenthal , Milan , Italy ) administer . Patients experimental group treat continuous regimen , patient control group receive OC cyclic regimen consist 21 day active pill 7 day placebo . The drug placebo similar label accord subject number . For overall study-period , operator patient blind treatment allocation .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Premenopausal state Endometriosisrelated chronic pelvic pain Hystologically confirm endometriosis laparoscopy Subjective severity pelvic pain use visual analogue scale least 70 No immediate desire pregnancy Age ≤18 ≥ 40 Previous use drug treat CPP ( washout period 3 month ) , exclusion nonsteroidal antiinflammatory drug Contraindication estroprogestin compound Major medical disease Psychiatric disorder Pelvic inflammatory disease Adnexal patologies Unability complete daily diary History alcohol drug abuse</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>